{"nct_id":"NCT01123083","title":"Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2","status":"COMPLETED","status_verified_date":"2017-08","start_date":"2010-05-17","start_date_type":"ACTUAL","primary_completion_date":"2012-03-09","primary_completion_date_type":"ACTUAL","completion_date":"2012-03-09","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["GSK"]}